6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
Rhabdomyolysis B-OSE_Labeled_AE
and O
myopathy B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
Liver B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
The O
most O
commonly O
reported O
adverse O
reactions O
( O
incidence O
> O
= O
2 O
% O
) O
in O
patients O
treated O
with O
LIPITOR O
in O
placebo-controlled O
trials O
regardless O
of O
causality O
were O
: O
nasopharyngitis O
, O
arthralgia O
, O
diarrhea O
, O
pain O
in O
extremity O
, O
and O
urinary O
tract O
infection O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
at O
( O
1-800-438-1985 O
and O
www.pfizer.com O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
the O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

In O
the O
LIPITOR O
placebo-controlled O
clinical O
trial O
database O
of O
16,066 O
patients O
( O
8755 O
LIPITOR O
vs O
. O
7311 O
placebo O
; O
age O
range O
10-93 O
years O
, O
39 O
% O
women O
, O
91 O
% O
Caucasians O
, O
3 O
% O
Blacks O
, O
2 O
% O
Asians O
, O
4 O
% O
other O
) O
with O
a O
median O
treatment O
duration O
of O
53 O
weeks O
, O
9.7 O
% O
of O
patients O
on O
LIPITOR O
and O
9.5 O
% O
of O
the O
patients O
on O
placebo O
discontinued O
due O
to O
adverse O
reactions O
regardless O
of O
causality O
. O

The O
five O
most O
common O
adverse O
reactions O
in O
patients O
treated O
with O
LIPITOR O
that O
led O
to O
treatment O
discontinuation O
and O
occurred O
at O
a O
rate O
greater O
than O
placebo O
were O
: O
myalgia B-OSE_Labeled_AE
( O
0.7 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
0.5 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increase I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
and O
hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
increase I-OSE_Labeled_AE
( O
0.4 O
% O
) O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
( O
incidence O
> O
= O
2 O
% O
and O
greater O
than O
placebo O
) O
regardless O
of O
causality O
, O
in O
patients O
treated O
with O
LIPITOR O
in O
placebo O
controlled O
trials O
( O
n=8755 O
) O
were O
: O
nasopharyngitis B-OSE_Labeled_AE
( O
8.3 O
% O
) O
, O
arthralgia B-OSE_Labeled_AE
( O
6.9 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
6.8 O
% O
) O
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
( O
6.0 O
% O
) O
, O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
5.7 O
% O
) O
. O

Table O
3 O
summarizes O
the O
frequency O
of O
clinical O
adverse O
reactions O
, O
regardless O
of O
causality O
, O
reported O
in O
> O
= O
2 O
% O
and O
at O
a O
rate O
greater O
than O
placebo O
in O
patients O
treated O
with O
LIPITOR O
( O
n=8755 O
) O
, O
from O
seventeen O
placebo-controlled O
trials O
. O

Table O
3 O
. O

Clinical O
adverse O
reactions O
occurring O
in O
> O
= O
2 O
% O
in O
patients O
treated O
with O
any O
dose O
of O
LIPITOR O
and O
at O
an O
incidence O
greater O
than O
placebo O
regardless O
of O
causality O
( O
% O
of O
patients O
) O
. O

Adverse O
Reaction O
[ O
note O
: O
Adverse O
Reaction O
> O
= O
2 O
% O
in O
any O
dose O
greater O
than O
placebo O
] O
Any O
doseN=8755 O
10 O
mgN=3908 O
20 O
mgN=188 O
40 O
mgN=604 O
80 O
mgN=4055 O
PlaceboN=7311 O
Nasopharyngitis B-OSE_Labeled_AE
8.3 O
12.9 O
5.3 O
7.0 O
4.2 O
8.2 O
Arthralgia B-OSE_Labeled_AE
6.9 O
8.9 O
11.7 O
10.6 O
4.3 O
6.5 O
Diarrhea B-OSE_Labeled_AE
6.8 O
7.3 O
6.4 O
14.1 O
5.2 O
6.3 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
6.0 O
8.5 O
3.7 O
9.3 O
3.1 O
5.9 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
5.7 O
6.9 O
6.4 O
8.0 O
4.1 O
5.6 O
Dyspepsia B-OSE_Labeled_AE
4.7 O
5.9 O
3.2 O
6.0 O
3.3 O
4.3 O
Nausea B-OSE_Labeled_AE
4.0 O
3.7 O
3.7 O
7.1 O
3.8 O
3.5 O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
3.8 O
5.2 O
3.2 O
5.1 O
2.3 O
3.6 O
Muscle B-OSE_Labeled_AE
Spasms I-OSE_Labeled_AE
3.6 O
4.6 O
4.8 O
5.1 O
2.4 O
3.0 O
Myalgia B-OSE_Labeled_AE
3.5 O
3.6 O
5.9 O
8.4 O
2.7 O
3.1 O
Insomnia B-OSE_Labeled_AE
3.0 O
2.8 O
1.1 O
5.3 O
2.8 O
2.9 O
Pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2.3 O
3.9 O
1.6 O
2.8 O
0.7 O
2.1 O
Other O
adverse O
reactions O
reported O
in O
placebo-controlled O
studies O
include O
: O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
: O
malaise B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
; O
Digestive B-NonOSE_AE
system I-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
eructation B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
cholestasis B-OSE_Labeled_AE
; O
Musculoskeletal B-NonOSE_AE
system I-NonOSE_AE
: O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
fatigue I-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
joint B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
; O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
nutritional I-NonOSE_AE
system I-NonOSE_AE
: O
transaminases B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
test I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
creatine B-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
; O
Nervous B-NonOSE_AE
system I-NonOSE_AE
: O
nightmare B-OSE_Labeled_AE
; O
Respiratory B-NonOSE_AE
system I-NonOSE_AE
: O
epistaxis B-OSE_Labeled_AE
; O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
: O
urticaria B-OSE_Labeled_AE
; O
Special B-NonOSE_AE
senses I-NonOSE_AE
: O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
; O
Urogenital B-NonOSE_AE
system I-NonOSE_AE
: O
white B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
urine I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
. O

Anglo-Scandinavian O
Cardiac O
Outcomes O
Trial O
( O
ASCOT O
) O
In O
ASCOT O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
involving O
10,305 O
participants O
( O
age O
range O
40-80 O
years O
, O
19 O
% O
women O
; O
94.6 O
% O
Caucasians O
, O
2.6 O
% O
Africans O
, O
1.5 O
% O
South O
Asians O
, O
1.3 O
% O
mixed/other O
) O
treated O
with O
LIPITOR O
10 O
mg O
daily O
( O
n=5,168 O
) O
or O
placebo O
( O
n=5,137 O
) O
, O
the O
safety O
and O
tolerability O
profile O
of O
the O
group O
treated O
with O
LIPITOR O
was O
comparable O
to O
that O
of O
the O
group O
treated O
with O
placebo O
during O
a O
median O
of O
3.3 O
years O
of O
follow-up O
. O

Collaborative O
Atorvastatin O
Diabetes O
Study O
( O
CARDS O
) O
In O
CARDS O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
involving O
2,838 O
subjects O
( O
age O
range O
39-77 O
years O
, O
32 O
% O
women O
; O
94.3 O
% O
Caucasians O
, O
2.4 O
% O
South O
Asians O
, O
2.3 O
% O
Afro-Caribbean O
, O
1.0 O
% O
other O
) O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
treated O
with O
LIPITOR O
10 O
mg O
daily O
( O
n=1,428 O
) O
or O
placebo O
( O
n=1,410 O
) O
, O
there O
was O
no O
difference O
in O
the O
overall O
frequency O
of O
adverse O
reactions O
or O
serious O
adverse O
reactions O
between O
the O
treatment O
groups O
during O
a O
median O
follow-up O
of O
3.9 O
years O
. O

No O
cases O
of O
rhabdomyolysis B-NonOSE_AE
were O
reported O
. O

Treating O
to O
New O
Targets O
Study O
( O
TNT O
) O
In O
TNT O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
involving O
10,001 O
subjects O
( O
age O
range O
29-78 O
years O
, O
19 O
% O
women O
; O
94.1 O
% O
Caucasians O
, O
2.9 O
% O
Blacks O
, O
1.0 O
% O
Asians O
, O
2.0 O
% O
other O
) O
with O
clinically O
evident O
CHD B-Not_AE_Candidate
treated O
with O
LIPITOR O
10 O
mg O
daily O
( O
n=5006 O
) O
or O
LIPITOR O
80 O
mg O
daily O
( O
n=4995 O
) O
, O
there O
were O
more O
serious O
adverse O
reactions O
and O
discontinuations O
due O
to O
adverse O
reactions O
in O
the O
high-dose O
atorvastatin O
group O
( O
92 O
, O
1.8 O
% O
; O
497 O
, O
9.9 O
% O
, O
respectively O
) O
as O
compared O
to O
the O
low-dose O
group O
( O
69 O
, O
1.4 O
% O
; O
404 O
, O
8.1 O
% O
, O
respectively O
) O
during O
a O
median O
follow-up O
of O
4.9 O
years O
. O

Persistent O
transaminase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
( O
> O
=3 O
* O
ULN O
twice O
within O
4-10 O
days O
) O
occurred O
in O
62 O
( O
1.3 O
% O
) O
individuals O
with O
atorvastatin O
80 O
mg O
and O
in O
nine O
( O
0.2 O
% O
) O
individuals O
with O
atorvastatin O
10 O
mg O
. O
Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
CK I-OSE_Labeled_AE
( O
> O
= O
10 O
* O
ULN O
) O
were O
low O
overall O
, O
but O
were O
higher O
in O
the O
high-dose O
atorvastatin O
treatment O
group O
( O
13 O
, O
0.3 O
% O
) O
compared O
to O
the O
low-dose O
atorvastatin O
group O
( O
6 O
, O
0.1 O
% O
) O
. O

Incremental O
Decrease O
in O
Endpoints O
through O
Aggressive O
Lipid O
Lowering O
Study O
( O
IDEAL O
) O
In O
IDEAL O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
involving O
8,888 O
subjects O
( O
age O
range O
26-80 O
years O
, O
19 O
% O
women O
; O
99.3 O
% O
Caucasians O
, O
0.4 O
% O
Asians O
, O
0.3 O
% O
Blacks O
, O
0.04 O
% O
other O
) O
treated O
with O
LIPITOR O
80 O
mg/day O
( O
n=4439 O
) O
or O
simvastatin O
20-40 O
mg O
daily O
( O
n=4449 O
) O
, O
there O
was O
no O
difference O
in O
the O
overall O
frequency O
of O
adverse O
reactions O
or O
serious O
adverse O
reactions O
between O
the O
treatment O
groups O
during O
a O
median O
follow-up O
of O
4.8 O
years O
. O

Stroke O
Prevention O
by O
Aggressive O
Reduction O
in O
Cholesterol O
Levels O
( O
SPARCL O
) O
In O
SPARCL O
involving O
4731 O
subjects O
( O
age O
range O
21-92 O
years O
, O
40 O
% O
women O
; O
93.3 O
% O
Caucasians O
, O
3.0 O
% O
Blacks O
, O
0.6 O
% O
Asians O
, O
3.1 O
% O
other O
) O
without O
clinically O
evident O
CHD B-Not_AE_Candidate
but O
with O
a O
stroke B-Not_AE_Candidate
or O
transient B-Not_AE_Candidate
ischemic I-Not_AE_Candidate
attack I-Not_AE_Candidate
( O
TIA O
) O
within O
the O
previous O
6 O
months O
treated O
with O
LIPITOR O
80 O
mg O
( O
n=2365 O
) O
or O
placebo O
( O
n=2366 O
) O
for O
a O
median O
follow-up O
of O
4.9 O
years O
, O
there O
was O
a O
higher O
incidence O
of O
persistent O
hepatic B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
( O
> O
= O
3 O
* O
ULN O
twice O
within O
4-10 O
days O
) O
in O
the O
atorvastatin O
group O
( O
0.9 O
% O
) O
compared O
to O
placebo O
( O
0.1 O
% O
) O
. O

Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
CK I-OSE_Labeled_AE
( O
> O
10 O
* O
ULN O
) O
were O
rare O
, O
but O
were O
higher O
in O
the O
atorvastatin O
group O
( O
0.1 O
% O
) O
compared O
to O
placebo O
( O
0.0 O
% O
) O
. O

Diabetes B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
144 O
subjects O
( O
6.1 O
% O
) O
in O
the O
atorvastatin O
group O
and O
89 O
subjects O
( O
3.8 O
% O
) O
in O
the O
placebo O
group O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

In O
a O
post-hoc O
analysis O
, O
LIPITOR O
80 O
mg O
reduced O
the O
incidence O
of O
ischemic B-Not_AE_Candidate
stroke I-Not_AE_Candidate
( O
218/2365 O
, O
9.2 O
% O
vs O
. O
274/2366 O
, O
11.6 O
% O
) O
and O
increased O
the O
incidence O
of O
hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
( O
55/2365 O
, O
2.3 O
% O
vs O
. O
33/2366 O
, O
1.4 O
% O
) O
compared O
to O
placebo O
. O

The O
incidence O
of O
fatal B-NonOSE_AE
hemorrhagic B-NonOSE_AE
stroke I-NonOSE_AE
was O
similar O
between O
groups O
( O
17 O
LIPITOR O
vs O
. O
18 O
placebo O
) O
. O

The O
incidence O
of O
non-fatal O
hemorrhagic B-OSE_Labeled_AE
strokes I-OSE_Labeled_AE
was O
significantly O
greater O
in O
the O
atorvastatin O
group O
( O
38 O
non-fatal O
hemorrhagic B-OSE_Labeled_AE
strokes I-OSE_Labeled_AE
) O
as O
compared O
to O
the O
placebo O
group O
( O
16 O
non-fatal O
hemorrhagic B-NonOSE_AE
strokes I-NonOSE_AE
) O
. O

Subjects O
who O
entered O
the O
study O
with O
a O
hemorrhagic B-Not_AE_Candidate
stroke I-Not_AE_Candidate
appeared O
to O
be O
at O
increased O
risk O
for O
hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
[ O
7 O
( O
16 O
% O
) O
LIPITOR O
vs O
. O
2 O
( O
4 O
% O
) O
placebo O
] O
. O

There O
were O
no O
significant O
differences O
between O
the O
treatment O
groups O
for O
all-cause O
mortality B-NonOSE_AE
: O
216 O
( O
9.1 O
% O
) O
in O
the O
LIPITOR O
80 O
mg/day O
group O
vs O
. O
211 O
( O
8.9 O
% O
) O
in O
the O
placebo O
group O
. O

The O
proportions O
of O
subjects O
who O
experienced O
cardiovascular B-NonOSE_AE
death I-NonOSE_AE
were O
numerically O
smaller O
in O
the O
LIPITOR O
80 O
mg O
group O
( O
3.3 O
% O
) O
than O
in O
the O
placebo O
group O
( O
4.1 O
% O
) O
. O

The O
proportions O
of O
subjects O
who O
experienced O
non-cardiovascular O
death B-NonOSE_AE
were O
numerically O
larger O
in O
the O
LIPITOR O
80 O
mg O
group O
( O
5.0 O
% O
) O
than O
in O
the O
placebo O
group O
( O
4.0 O
% O
) O
. O

Adverse O
Reactions O
from O
Clinical O
Studies O
of O
LIPITOR O
in O
Pediatric O
Patients O
In O
a O
26-week O
controlled O
study O
in O
boys O
and O
postmenarchal O
girls O
with O
HeFH O
( O
ages O
10 O
years O
to O
17 O
years O
) O
( O
n=140 O
, O
31 O
% O
female O
; O
92 O
% O
Caucasians O
, O
1.6 O
% O
Blacks O
, O
1.6 O
% O
Asians O
, O
4.8 O
% O
other O
) O
, O
the O
safety O
and O
tolerability O
profile O
of O
LIPITOR O
10 O
to O
20 O
mg O
daily O
, O
as O
an O
adjunct O
to O
diet O
to O
reduce B-Not_AE_Candidate
total I-Not_AE_Candidate
cholesterol I-Not_AE_Candidate
, O
LDL-C O
, O
and O
apo O
B O
levels O
, O
was O
generally O
similar O
to O
that O
of O
placebo O
[ O
see O
Use O
in O
Special O
Populations O
( O
8.4 O
) O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
LIPITOR O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Adverse O
reactions O
associated O
with O
LIPITOR O
therapy O
reported O
since O
market O
introduction O
, O
that O
are O
not O
listed O
above O
, O
regardless O
of O
causality O
assessment O
, O
include O
the O
following O
: O
anaphylaxis B-OSE_Labeled_AE
, O
angioneurotic B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
bullous B-OSE_Labeled_AE
rashes I-OSE_Labeled_AE
( O
including O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
) O
, O
rhabdomyolysis B-OSE_Labeled_AE
, O
myositis B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
, O
fatal B-NonOSE_AE
and O
non-fatal O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
and O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

There O
have O
been O
rare O
reports O
of O
immune B-OSE_Labeled_AE
- I-OSE_Labeled_AE
mediated I-OSE_Labeled_AE
necrotizing I-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
associated O
with O
statin O
use O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

There O
have O
been O
rare O
postmarketing O
reports O
of O
cognitive B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
( O
e.g. O
, O
memory B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
forgetfulness B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
) O
associated O
with O
statin O
use O
. O

These O
cognitive B-OSE_Labeled_AE
issues I-OSE_Labeled_AE
have O
been O
reported O
for O
all O
statins O
. O

The O
reports O
are O
generally O
nonserious O
, O
and O
reversible O
upon O
statin O
discontinuation O
, O
with O
variable O
times O
to O
symptom O
onset O
( O
1 O
day O
to O
years O
) O
and O
symptom O
resolution O
( O
median O
of O
3 O
weeks O
) O
. O

